PKCα overexpression is a predictor of a poor prognosis and drug resistance in breast [24,25,26,27,28,29]; lung [30,31,32]; prostate [33]; ovarian [34,35,36]; and hepatocellular cancer [37]; and melanoma [38,39,40] and glioma [41,42,43], among others. Here, PRKCA is linked to glioma.